Idelalisib for the treatment of non-Hodgkin lymphoma
Authors:
- 4 January 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 17 (2) , 265-274
Abstract
IntroductionB-cell Non-Hodgkin lymphomas (B-NHLs) include a number of disease subtypes, each defined by the tempo of disease progression and the identity of the cancerous cell. Idelalisib is a pote...Keywords
Funding Information
- Fred Hutchinson Cancer Center (P30 CA015704)
- National Institutes of Health (5T32HL007093, K24CA184039, P01CA44991)
This publication has 61 references indexed in Scilit:
- Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trialThe Lancet Oncology, 2011
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBlood, 2011
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood, 2010
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström MacroglobulinemiaAmerican Journal of Hematology, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Outcome of Deferred Initial Therapy in Mantle-Cell LymphomaJournal of Clinical Oncology, 2009
- The 2008 WHO classification of lymphomas: implications for clinical practice and translational researchHematology-American Society Hematology Education Program, 2009
- Lenalidomide and Rituximab in Waldenstrom's MacroglobulinemiaClinical Cancer Research, 2008
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007